Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was €1,307.9 Mil.
Xeris Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €33.6 Mil. Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 2.54%.
The historical rank and industry rank for Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:2B30'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4561.6 Med: -28 Max: 1921.52
Current: 2.49
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of Xeris Biopharma Holdings was 1921.52%. The lowest was -4561.60%. And the median was -28.00%.
FRA:2B30's Earnings Yield (Joel Greenblatt) % is ranked worse than 52.38% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 2.92
vs FRA:2B30: 2.49
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Xeris Biopharma Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Xeris Biopharma Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Xeris Biopharma Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Xeris Biopharma Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Xeris Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.6 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 2.54% mean?
Xeris Biopharma Holdings (FRA:2B30) has a Earnings Yield (Joel Greenblatt) % of 2.54% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Xeris Biopharma Holdings and its competitors. According to the industry distribution chart, Xeris Biopharma Holdings ranks #529 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Xeris Biopharma Holdings' Earnings Yield (Joel Greenblatt) % too high?
Xeris Biopharma Holdings' current Earnings Yield (Joel Greenblatt) % is 2.54%. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 2.92. Xeris Biopharma Holdings' value of 2.54% is 13% below this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #529 out of 1010 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Earnings Yield (Joel Greenblatt) % compare to PAHC and ANIP?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #529 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 2.92. Xeris Biopharma Holdings' value of 2.54% is 13% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 2.92, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Earnings Yield (Joel Greenblatt) % of 2.54% is 13% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Earnings Yield (Joel Greenblatt) % is 2.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.65, compared to a current price of €7.16 — trading 54.1% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 2.54% and 13% below the Drug Manufacturers industry median of 2.92. Xeris Biopharma Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Earnings Yield (Joel Greenblatt) % is 2.54% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.16 is trading 54.1% above its estimated GF Value™ of €4.65.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
Earnings Yield (Joel Greenblatt) %: 2.54%
GF Value™: €4.65 vs. price of €7.16 (54.1% above fair value)
Industry Position: 13% below the Drug Manufacturers median (#529 of 1010)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
73GF Score
Get the complete analysis for FRA:2B30
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
